查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1573979

鬱血性心臟衰竭：按類型、診斷、治療和最終用戶分類 - 全球預測 2025-2030

Congestive Heart Failure Market by Type (Left-Sided Heart Failure, Right-Sided Heart Failure), Diagnosis (Blood Tests, Electrocardiogram, Imaging Tests), Treatment, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年鬱血性心臟衰竭市值為64.3億美元，預計2024年將達到67.9億美元，複合年成長率為7.31%，到2030年將達到105.4億美元。

鬱血性心臟衰竭（CHF）是一種嚴重的疾病，其特徵是心臟無法有效泵血，影響各種身體功能。 CHF 的範圍和定義包括冠狀動脈疾病、高血壓和糖尿病等疾病導致的心臟生理性衰竭。隨著這些疾病的日益流行，對有效管理和治療解決方案的需求變得至關重要。 CHF 的治療包括藥物介入、生活型態改變、外科手術以及心律調節器和輔助人工心臟等新技術。就最終用途而言，市場範圍涵蓋醫院、心臟中心、門診手術中心和居家照護機構。 CHF 市場的主要成長動力包括人口老化、醫療保健意識的提高以及先進醫療技術的採用。人工智慧和遠端醫療的最新進展為加強病患監測和個人化治療計劃提供了重要機會。利用這些機會的建議包括投資數位健康解決方案以及與高科技公司合作開發創新產品。然而，由於高昂的治療成本、嚴格的法律規範以及醫療保健系統報銷的複雜性，市場成長面臨限制。應對這些挑戰需要對具有成本效益的技術進行策略性投資，並採取強力的合規措施來應對監管環境。創新和研究的最佳領域包括開發針對慢性心臟衰竭根本原因的新型藥物療法以及用於早期檢測的非侵入性診斷工具。基因治療和再生醫學也具有巨大潛力。對 CHF 市場的洞察揭示了由技術創新和以患者為中心的護理需求驅動的動態環境。為了發展您的業務，請專注於協作研究，加強您現有的產品系列，並擴大您的地理覆蓋範圍，以便在這個不斷發展的市場中獲得競爭優勢。

主要市場統計
基準年[2023] 64.3億美元
預測年份 [2024] 67.9億美元
預測年份 [2030] 105.4億美元
複合年成長率（%） 7.31%

市場動態：揭示快速發展的鬱血性心臟衰竭市場的關鍵市場洞察

供需的動態交互作用正在改變鬱血性心臟衰竭市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 對微創手術和心臟衰竭治療程序的需求不斷成長
    • 擴大新興市場的醫療服務範圍並改善診斷設施
    • 製藥公司之間在藥物開發的聯盟與合作增加
    • 提高病患對早期診斷和管理方案的認知和教育舉措
  • 市場限制因素
    • 具有鬱血性心臟衰竭專業知識的專業醫療保健提供者的數量有限
    • 高合併症使鬱血性的治療和結果變得複雜，降低了市場有效性
  • 市場機會
    • 將人工智慧和機器學習整合到鬱血性心臟衰竭和治療中
    • 充血心臟衰竭鬱血性微創外科技術治療進展
    • 利用患者特定資料制定個人化鬱血性心臟衰竭計劃
  • 市場挑戰
    • 加強監管，影響鬱血性心臟衰竭的核准和分配
    • 新生物技術和鬱血性心臟衰竭療法的競爭加劇

波特五力：駕馭鬱血性心臟衰竭的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解鬱血性心臟衰竭的外部影響

外部宏觀環境因素在塑造鬱血性心臟衰竭的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助企業預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解鬱血性心臟衰竭的競爭格局

對鬱血性心臟衰竭的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣鬱血性心臟衰竭供應商的績效評估

FPNV定位矩陣是評估鬱血性心臟衰竭供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了鬱血性心臟衰竭的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對鬱血性心臟衰竭市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：全面分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 對微創手術和心臟衰竭治療程序的需求增加
      • 擴大新興市場的醫療服務範圍並改善診斷設施
      • 加強製藥公司在藥物開發方面的聯盟與合作
      • 擴大患者對早期診斷和治療選擇的認知和教育工作
    • 抑制因素
      • 具有鬱血性心臟衰竭專業知識的專業醫療保健提供者的數量有限
      • 合併症的高盛行率使鬱血性心臟衰竭的治療和結果變得複雜，從而降低了市場有效性。
    • 機會
      • 將人工智慧和機器學習整合到鬱血性心臟衰竭和治療中
      • 充血心臟衰竭鬱血性微創外科技術治療進展
      • 利用患者特定資料制定個人化鬱血性心臟衰竭計劃
    • 任務
      • 加強監管會影響鬱血性心臟衰竭的核准和分配
      • 新興生物技術和替代治療方法加劇了鬱血性的競爭
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章鬱血性心臟衰竭：依類型

  • 左心臟衰竭
    • 舒張性心衰竭
    • 收縮性心臟衰竭
  • 右心臟衰竭

第7章鬱血性心臟衰竭市場

  • 驗血
    • 腦鈉肽測試
    • 電解質水平測試
    • NT-proBNP 測試
  • 心電圖
  • 影像檢查
    • 電腦斷層掃描
    • 心臟超音波圖
    • MRI
  • 壓力測試
    • 運動壓力測試
    • 核子壓力測試

第8章鬱血性心臟衰竭市場

  • 醫療設備
    • 心臟再同步治療裝置
    • 植入式心臟整流去顫器
    • 心律調節器
  • 藥品
    • ACE抑制劑
    • 醛固酮拮抗劑
    • BETA受體阻斷劑
    • 利尿劑
    • 血管擴張劑
  • 外科手術
    • 冠狀動脈繞道術
    • 心臟瓣膜修復或更換

第9章鬱血性心臟衰竭：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 專科診所

第10章美洲鬱血性心臟衰竭

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太鬱血性心臟衰竭

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲鬱血性心臟衰竭市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-1A1A064C04DC

The Congestive Heart Failure Market was valued at USD 6.43 billion in 2023, expected to reach USD 6.79 billion in 2024, and is projected to grow at a CAGR of 7.31%, to USD 10.54 billion by 2030.

Congestive Heart Failure (CHF) is a significant medical condition characterized by the heart's inability to pump blood effectively, impacting various bodily functions. The scope and definition of CHF encompass the physiological inadequacies of the heart, often due to conditions such as coronary artery disease, hypertension, or diabetes. With the increasing prevalence of these conditions, the necessity for effective management and treatment solutions is paramount. The application of treatments for CHF includes pharmacological interventions, lifestyle modifications, surgical procedures, and emerging technologies like pacemakers and ventricular assist devices. In terms of end-use, the market scope spans hospitals, cardiac centers, ambulatory surgical centers, and home care settings. Key growth drivers in the CHF market include an aging population, rising healthcare awareness, and the adoption of advanced healthcare technologies. Recent advancements in AI and telemedicine offer substantial opportunities for enhancing patient monitoring and personalized treatment plans. Recommendations to capitalize on these opportunities include investing in digital health solutions and forming partnerships with tech companies for innovative product development. Market growth, however, faces limitations due to high treatment costs, stringent regulatory frameworks, and the complex nature of healthcare system reimbursements. Addressing these challenges requires strategic investment in cost-effective technologies and navigating regulatory landscapes with robust compliance measures. Best areas for innovation and research include the development of novel drug therapies targeting the underlying causes of CHF, and non-invasive diagnostic tools for early detection. Exploring gene therapy and regenerative medicine also presents immense potential. Insight into the CHF market reveals a dynamic environment driven by technological innovation and patient-centric care demands. For business growth, a focus on collaborative research, enhancing existing product portfolios, and expanding geographic reach can provide competitive advantages in this evolving market.

KEY MARKET STATISTICS
Base Year [2023] USD 6.43 billion
Estimated Year [2024] USD 6.79 billion
Forecast Year [2030] USD 10.54 billion
CAGR (%) 7.31%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Congestive Heart Failure Market

The Congestive Heart Failure Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising demand for minimally invasive surgeries and heart failure management procedures
    • Expanding healthcare access and improving diagnostic facilities in emerging markets
    • Increasing partnerships and collaborations among pharmaceutical companies for drug development
    • Growing patient awareness and education initiatives regarding early diagnosis and management options
  • Market Restraints
    • Limited availability of specialized healthcare providers with expertise in congestive heart failure management
    • High prevalence of comorbidities complicates congestive heart failure treatment and outcomes, reducing market effectiveness
  • Market Opportunities
    • Integration of artificial intelligence and machine learning in congestive heart failure diagnosis and treatment
    • Advancement of minimally invasive surgical techniques for congestive heart failure treatment
    • Utilization of patient-specific data in personalized congestive heart failure treatment plans
  • Market Challenges
    • Heightened regulatory scrutiny impacting approval and distribution of congestive heart failure therapies
    • Increased competition from emerging biotechnologies and alternative treatments for congestive heart failure

Porter's Five Forces: A Strategic Tool for Navigating the Congestive Heart Failure Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Congestive Heart Failure Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Congestive Heart Failure Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Congestive Heart Failure Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Congestive Heart Failure Market

A detailed market share analysis in the Congestive Heart Failure Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Congestive Heart Failure Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Congestive Heart Failure Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Congestive Heart Failure Market

A strategic analysis of the Congestive Heart Failure Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Congestive Heart Failure Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amgen Inc., AstraZeneca, Bayer AG, Biotronik, Boston Scientific Corporation, Bristol-Myers Squibb Company, CVRx, Inc., Eli Lilly and Company, GlaxoSmithKline plc, HeartWare International Inc., Johnson & Johnson, Medtronic plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., ResMed, Sanofi S.A., Teleflex Incorporated, and Thoratec Corporation.

Market Segmentation & Coverage

This research report categorizes the Congestive Heart Failure Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Left-Sided Heart Failure and Right-Sided Heart Failure. The Left-Sided Heart Failure is further studied across Diastolic Heart Failure and Systolic Heart Failure.
  • Based on Diagnosis, market is studied across Blood Tests, Electrocardiogram, Imaging Tests, and Stress Tests. The Blood Tests is further studied across BNP Test, Electrolyte Level Test, and NT-proBNP Test. The Imaging Tests is further studied across CT Scan, Echocardiogram, and MRI. The Stress Tests is further studied across Exercise Stress Test and Nuclear Stress Test.
  • Based on Treatment, market is studied across Medical Devices, Medications, and Surgical Procedures. The Medical Devices is further studied across Cardiac Resynchronization Therapy Devices, Implantable Cardioverter Defibrillators, and Pacemakers. The Medications is further studied across ACE Inhibitors, Aldosterone Antagonists, Beta Blockers, Diuretics, and Vasodilators. The Surgical Procedures is further studied across Coronary Bypass Surgery and Heart Valve Repair or Replacement.
  • Based on End User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising demand for minimally invasive surgeries and heart failure management procedures
      • 5.1.1.2. Expanding healthcare access and improving diagnostic facilities in emerging markets
      • 5.1.1.3. Increasing partnerships and collaborations among pharmaceutical companies for drug development
      • 5.1.1.4. Growing patient awareness and education initiatives regarding early diagnosis and management options
    • 5.1.2. Restraints
      • 5.1.2.1. Limited availability of specialized healthcare providers with expertise in congestive heart failure management
      • 5.1.2.2. High prevalence of comorbidities complicates congestive heart failure treatment and outcomes, reducing market effectiveness
    • 5.1.3. Opportunities
      • 5.1.3.1. Integration of artificial intelligence and machine learning in congestive heart failure diagnosis and treatment
      • 5.1.3.2. Advancement of minimally invasive surgical techniques for congestive heart failure treatment
      • 5.1.3.3. Utilization of patient-specific data in personalized congestive heart failure treatment plans
    • 5.1.4. Challenges
      • 5.1.4.1. Heightened regulatory scrutiny impacting approval and distribution of congestive heart failure therapies
      • 5.1.4.2. Increased competition from emerging biotechnologies and alternative treatments for congestive heart failure
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Congestive Heart Failure Market, by Type

  • 6.1. Introduction
  • 6.2. Left-Sided Heart Failure
    • 6.2.1. Diastolic Heart Failure
    • 6.2.2. Systolic Heart Failure
  • 6.3. Right-Sided Heart Failure

7. Congestive Heart Failure Market, by Diagnosis

  • 7.1. Introduction
  • 7.2. Blood Tests
    • 7.2.1. BNP Test
    • 7.2.2. Electrolyte Level Test
    • 7.2.3. NT-proBNP Test
  • 7.3. Electrocardiogram
  • 7.4. Imaging Tests
    • 7.4.1. CT Scan
    • 7.4.2. Echocardiogram
    • 7.4.3. MRI
  • 7.5. Stress Tests
    • 7.5.1. Exercise Stress Test
    • 7.5.2. Nuclear Stress Test

8. Congestive Heart Failure Market, by Treatment

  • 8.1. Introduction
  • 8.2. Medical Devices
    • 8.2.1. Cardiac Resynchronization Therapy Devices
    • 8.2.2. Implantable Cardioverter Defibrillators
    • 8.2.3. Pacemakers
  • 8.3. Medications
    • 8.3.1. ACE Inhibitors
    • 8.3.2. Aldosterone Antagonists
    • 8.3.3. Beta Blockers
    • 8.3.4. Diuretics
    • 8.3.5. Vasodilators
  • 8.4. Surgical Procedures
    • 8.4.1. Coronary Bypass Surgery
    • 8.4.2. Heart Valve Repair or Replacement

9. Congestive Heart Failure Market, by End User

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers
  • 9.3. Hospitals
  • 9.4. Specialty Clinics

10. Americas Congestive Heart Failure Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Congestive Heart Failure Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Congestive Heart Failure Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

LIST OF FIGURES

  • FIGURE 1. CONGESTIVE HEART FAILURE MARKET RESEARCH PROCESS
  • FIGURE 2. CONGESTIVE HEART FAILURE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CONGESTIVE HEART FAILURE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CONGESTIVE HEART FAILURE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CONGESTIVE HEART FAILURE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CONGESTIVE HEART FAILURE MARKET DYNAMICS
  • TABLE 7. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIASTOLIC HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SYSTOLIC HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY BNP TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ELECTROLYTE LEVEL TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY NT-PROBNP TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ELECTROCARDIOGRAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CT SCAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ECHOCARDIOGRAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY MRI, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY EXERCISE STRESS TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY NUCLEAR STRESS TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY IMPLANTABLE CARDIOVERTER DEFIBRILLATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY PACEMAKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ALDOSTERONE ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIURETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY VASODILATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CORONARY BYPASS SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY HEART VALVE REPAIR OR REPLACEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 97. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 99. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 100. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 101. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 103. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 113. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 114. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 115. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 116. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 130. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 132. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 134. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 136. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 138. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 140. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 143. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 144. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 145. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 146. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 147. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 148. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 149. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 150. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 151. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 152. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 154. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 155. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 156. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 157. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 158. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 159. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 160. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 161. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 162. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 165. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 166. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 167. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 168. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 169. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 170. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 171. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 172. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 173. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 174. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 176. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 177. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 178. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 179. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 180. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 181. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 182. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 183. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 184. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 187. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 188. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 189. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 190. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 191. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 192. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 193. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 194. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 195. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 196. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 198. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 199. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 200. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 201. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 202. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 203. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 204. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 205. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 206. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 207. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 209. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 210. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 211. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 212. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 213. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 214. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 215. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 216. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 217. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 218. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 220. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 221. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 222. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 223. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 224. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 225. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 226. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 227. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 228. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 229. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 231. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 232. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 233. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 234. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 235. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 236. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 237. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 238. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 239. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 240. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 242. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 243. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 244. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 245. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 246. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 247. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 248. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 249. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 250. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 251. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 253. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 254. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 255. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 256. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 257. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 258. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 259. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 260. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 261. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 274. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 276. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 277. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 278. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 279. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 280. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 281. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 282. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 283. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 284. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 285. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 287. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 288. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 289. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 290. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 291. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 292. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 293. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 294. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 295. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 296. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 297. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 298. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 299. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 300. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 301. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 302. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 303. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 304. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 305. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 306. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 307. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 308. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 309. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 310. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 311. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 312. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 313. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 314. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 315. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 316. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 317. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 318. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 319. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 320. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 321. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 322. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 323. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
  • TABLE 324. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 325. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 326. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 327. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDU